未知股票 PROC 深 沪
已收盘 02-04 16:00:00 美东时间
0.00
0.000
NaN.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.00
- 总市值 0
- 52周最高 --
- 市盈率 静 0.00
- 换手率 0.00%
- 52周最低 --
- 委 比 0.00%
- 总股本 1.13亿
- 历史最高 --
- 量 比 0
- 振 幅 NaN.00%
- 历史最低 --
- 每 手 1
- 风险率 0.61%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多康宁杰瑞制药(09966.HK)JSKN003治疗PROC获FDA突破性疗法认定 盘中涨逾7%
【财华社讯】康宁杰瑞制药-B(09966.HK)午后一度涨逾7%，截至发稿，涨4.5%，报10.69港元。消息面上，该公司午间公布，JSKN003已获美国食品药...
2025-12-18 13:32
Class Action Announcement STUB: A Securities Fraud Class Action Lawsuit Was Filed Against StubHub Holdings, Inc. (STUB)
RADNOR, Pa., Nov. 29, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against ...
2025-11-29 23:40
POWER METALLIC ANNOUNCES AGSM MEETING RESULTS & UPDATE ON NYSE PROCESS
TORONTO, Nov. 25, 2025 /PRNewswire/ -- Power Metallic Mines Inc. (the "Company" or "Power Metallic") (TSXV: PNPN) (OTCBB: PNPNF) (Frankfurt: IVV) is pleased to announce the voting results fr...
2025-11-25 16:03
BLUE WATER ACQUISITION CORP. III SUSPENDS PARTICIPATION IN CITGO ACQUISITION PROCESS
NEW YORK, Nov. 14, 2025 /PRNewswire/ -- Blue Water Acquisition Corp. III ("Blue Water") today announced that, after a comprehensive review, the Company has elected to suspend participation i...
2025-11-15 05:31
Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress
Zentalis Pharmaceuticals announced the continuation of its Phase 2 DENALI trial of azenosertib for Cyclin E1-positive platinum-resistant ovarian cancer (PROC), targeting topline data by end of 2026, with potential for accelerated FDA approval. The company reported $280.7 million in cash, supporting operations into late 2027, along with decreased R&D and G&A expenses. Additionally, the TETON trial in uterine serous carcinoma completed enrollment.
2025-11-10 21:05
Immunocore reports third quarter financial results and provides a business update
Immunocore reported third-quarter net product sales of $103.7 million for KIMMTRAK, up 29% year-over-year, with progress in Phase 3 trials and dosing updates. Cash reserves stood at $892 million.
2025-11-06 12:00
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zentalis Pharmaceuticals granted non-qualified stock options to purchase 17,000 shares to a newly hired employee under the 2022 Inducement Plan. The options have an exercise price of $1.44 and vest over four years. Zentalis is developing a potentially first-in-class WEE1 inhibitor for ovarian cancer patients.
2025-11-03 22:25
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
Zentalis Pharmaceuticals announced that its management team will participate in two upcoming investor conferences: Guggenheim's 2nd Annual Healthcare Innovation Conference in Boston on November 11, 2025, and Stifel's 2025 Healthcare Conference in New York on November 12, 2025. Zentalis is developing azenosertib (ZN-c3), a potential first-in-class WEE1 inhibitor for ovarian cancer. More details about the events and presentations are available on t...
2025-11-03 13:15
康宁杰瑞制药-B(09966.HK)JSKN003获美国FDA授予用于治疗PROC的FTD
【财华社讯】康宁杰瑞制药-B(09966.HK)公布，JSKN003已获美国食品药品监督管理局(FDA)授予快速通道资格认定(“FTD”)，用于治疗不限人表皮生...
2025-10-28 11:31
康宁杰瑞制药-B(09966.HK)：JSKN003再次获得CDE突破性疗法认定
康宁杰瑞制药-B(09966.HK)发布公告，与石药集团有限公司(股份代号：1093)附属公司上海津曼特生物科技有限公司合作开发的JSKN003获得CDE突破性疗法认定，用于治疗既往经奥沙利铂、氟尿嘧啶和伊立替康治疗失败的HER2+ 晚期CRC患者。
2025-10-20 08:40
